TGF-β and CXCL12 appear to modulate the relative populations of tumor infiltrating lymphocytes and their respective activities; this has been demonstrated by studies showing the blockade of TGF-β or CXCL12 to potentiate tumor responses to immune checkpoint blockades across multiple tumor models [71,139,140,141]. The gene discussed is CXCL12; the disease is neoplasm.